2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-172904
    Antidiabetic agent 15 98%
    Antidiabetic agent 15 (compound 1B15) is a AT1R and NEP dual inhibitor. Antidiabetic agent 15 reduces the oxidative stress and restores the mitochondrial membrane potential.
    Antidiabetic agent 15
  • HY-172905
    BCX-3607 885684-79-7 98%
    BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC50: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases.
    BCX-3607
  • HY-172914
    ACLY-IN-1 2897695-26-8 98%
    ACLY-IN-1 (compound 55) is a potent ACLY inhibitor with an IC50 of 8.3 nM. ACLY-IN-1 can be used in the study of hyperlipidemia.
    ACLY-IN-1
  • HY-172959
    mPTP-IN-1 554414-59-4 98%
    mPTP-IN-1 (Compound 14e) is a mitochondrial permeability transition pore (mPTP) inhibitor. mPTP-IN-1 blocks calcium-induced mPTP opening by targeting the C subunit of ATP synthase. mPTP-IN-1 can be used to study myocardial ischemia/reperfusion injury (IRI).
    mPTP-IN-1
  • HY-173005
    JZ19 98%
    JZ19 reduces the LDH and ROS levels, and exhibits antioxidant activity against oxygen-glucose deprivation (OGD)-induced cardiomyocyte injury. JZ19 reverses Isoproterenol (HY-B0468)-induced cardiomyocyte hypertrophy and apoptosis through PI3K-AKT-GSK3β signaling pathway. JZ19 alleviates Isoproterenol (HY-B0468)-induced heart failure in mouse models.
    JZ19
  • HY-173207
    Antiplatelet agent 3 1623073-71-1 98%
    Antiplatelet agent 3 (Compound K-10) is a compound with anti-platelet aggregation activity. The IC50 values for platelet aggregation induced by ADP, AA and COL are 2.55, 3.22 and 2.09 mg/mL, respectively. Antiplatelet agent 3 is expected to be used in the research of cardiovascular diseases.
    Antiplatelet agent 3
  • HY-173217
    PPARα agonist 5 98%
    PPARα agonist 5 is an orally available, selective partial agonist of PPARα (EC50: 3 nM). PPARα agonist 5 reduces lipid accumulation and upregulates key PPARα target genes, exerting anti-fatty liver effects. PPARα agonist 5 also exhibits significant hypolipidemic and hypoglycemic effects through partial PPARγ agonist activity and mild inhibition of protein tyrosine phosphatase 1B (PTP1B) (IC50: 79.1 μM). PPARα agonist 5 has a good safety profile and can be used in the study of type 2 diabetes with dyslipidemia.
    PPARα agonist 5
  • HY-173234
    GI-Y2 1008710-58-4 98%
    GI-Y2 is an inhibitor of GSDMD and can inhibit Pyroptosis of macrophages induced by oxidized low-density lipoprotein (ox-LDL). In vivo, GI-Y2 can dose-dependently reduce atherosclerotic plaques in ApoE-/- mice and decrease the lesion size and fibrosis degree of the aortic root. GI-Y2 is expected to be used in the research of pyroptosis and cardiovascular diseases, such as atherosclerosis.
    GI-Y2
  • HY-173235
    Galectin-3-IN-6 2604662-64-6 98%
    Galectin-3-IN-6 (Compound 12) is an orally active inhibitor of galectin-3 (Gal-3), with an IC50 value of 12 nM and a Kd value of 13 nM for Gal-3. In a mouse model of acute liver injury and fibrosis induced by CCl4, Galectin-3-IN-6 can significantly reduce the levels of fibrosis markers collagen-1 and α-smooth muscle actin (αSMA) by 64% and 71%, respectively, showing significant anti-fibrotic activity. Galectin-3-IN-6 can be used in the research of fibrotic diseases, cancer, and cardiovascular diseases.
    Galectin-3-IN-6
  • HY-173272
    BT-114143 2796343-04-7 98%
    BT-114143 is a plasminogen activation inhibitor, with an IC50 of 8.42 μM. BT-114143 can be used in the research of hemorrhagic diseases caused by hyperfibrinolysis, such as traumatic bleeding, severe menstrual bleeding, postpartum hemorrhage, and complications of hemophilia.
    BT-114143
  • HY-173294
    NLRP3-IN-74 98%
    NLRP3-IN-74 (Compound 11) is an orally active NLRP3 inhibitor with an IC50 value of 2.7 μM. NLRP3-IN-74 can inhibit the release of IL-1β, reducing the release level by approximately 90%, and does not inhibit the release of TNFα. NLRP3-IN-74 can be used in the research of related diseases such as atherosclerosis and Parkinson's disease.
    NLRP3-IN-74
  • HY-173307
    Nrf2 activator 19 98%
    Nrf2 activator 19 is a BBB-penetrable NRF2/HO-1 activator. Nrf2 activator 19 exerts potent antioxidant and neuroprotective effects. Nrf2 activator 19 can also effectively reduce brain damage, reduce Reactive Oxygen Species (ROS) accumulation. Nrf2 activator 19 inhibits neuronal apoptosis. Nrf2 activator 19 promotes the recovery of neurological function and motor ability. Nrf2 activator 19 shows significant potential in ischemic stroke research.
    Nrf2 activator 19
  • HY-173313
    Ferroptosis-IN-19 3025114-13-7 98%
    Ferroptosis-IN-19 (compound C18) is a strong cellular ferroptosis inhibitor with an IC50 value of 0.097 μM. Ferroptosis-IN-19 shows high metabolic stability and favorable BBB permeability prediction. Ferroptosis-IN-19 has in vivo neuroprotection against ischemic brain injury in mice.
    Ferroptosis-IN-19
  • HY-173323
    Lp(a)-IN-7 3070232-49-1 98%
    Lp(a)-IN-7 (example 1) is a lipoprotein (a) (Lp(a)) formation inhibitor with an IC50 of 2.51 nM in conditioned media containing apolipoprotein B (apoB) and apolipoprotein(a). Lp(a)-IN-7 can be used for the study of cardiovascular disease.
    Lp(a)-IN-7
  • HY-173325
    LPA2 antagonist 6 3072671-88-3 98%
    LPA2 antagonist 6 (example 2) is an antagonist of Lp(a). LPA2 antagonist 6 inhibits Lp(a) formation with an IC50 value of 2.33 nM. LPA2 antagonist 6 can be used in the research of cardiovascular disease.
    LPA2 antagonist 6
  • HY-173360
    PDE10A-IN-5 98%
    PDE10A-IN-5 (Compound A30) is an inhibitor of phosphodiesterase 10A (PDE10A) with oral activity, and its IC50 value is 3.5 nM. PDE10A-IN-5 exerts the activity of inhibiting pulmonary vascular remodeling by inhibiting PDE10A and activating the cyclic adenosine monophosphate (cAMP)-associated signaling pathway, and can be used for research in the field of pulmonary arterial hypertension.
    PDE10A-IN-5
  • HY-173418
    Carbaprostacyclin-biotin
    Carbaprostacyclin-biotin (cPGI-biotin; Carbacyclin-biotin) is a biotin-bound Carbacyclin (Carbaprostacyclin) (HY-112322). Carbacyclin is a PGI2 analogue, acts as a prostacyclin (PGI2) receptor agonist and vasodilator, and potently inhibits platelet aggregation.
    Carbaprostacyclin-biotin
  • HY-173420
    15-Keto Iloprost 155326-57-1
    15-Keto Iloprost is a C-15 oxidized derivative of Iloprost (HY-A0096). Iloprost (ZK 36374) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis.
    15-Keto Iloprost
  • HY-173430
    AD015 177741-43-4 98%
    AD015 is a angiotensin-converting enzyme (ACE) and neprilysin (NEP) dual inhibitor. AD015 inhibits NEP, nACE and cACE with IC50s of 0.009, 0.019 and 0.0008 μM, respectively.
    AD015
  • HY-173479
    GLP-1R agonist 30 98%
    GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC50 of 0.048 nM. GLP-1R has excellent selectivity, with EC50 greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice.
    GLP-1R agonist 30
Cat. No. Product Name / Synonyms Application Reactivity